MARGENZA is a Intravenous Injection, Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Macrogenics, Inc. The primary component is Margetuximab.
| Product ID | 74527-022_30b9c9b4-90e1-4478-aad7-f8cae4dbf1dc | 
| NDC | 74527-022 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | MARGENZA | 
| Generic Name | Margetuximab-cmkb | 
| Dosage Form | Injection, Solution, Concentrate | 
| Route of Administration | INTRAVENOUS | 
| Marketing Start Date | 2021-01-15 | 
| Marketing Category | BLA / BLA | 
| Application Number | BLA761150 | 
| Labeler Name | MacroGenics, Inc | 
| Substance Name | MARGETUXIMAB | 
| Active Ingredient Strength | 25 mg/mL | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2021-12-31 | 
| Marketing Start Date | 2021-01-15 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  MARGENZA  88027290  not registered Live/Pending | MacroGenics, Inc. 2018-07-05 |